Wells Fargo & Company Sarepta Therapeutics, Inc. Call Options Transaction History

Wells Fargo & Company

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 13, 2023	SELL	$102.5 - $123.59 $1.35 Million - $1.63 Million	-13,200 Reduced 40.99%	19,000 $2.3 Million
Q2 2023 Aug 15, 2023	SELL	$106.4 - $157.19 $63,840 - $94,314	-600 Reduced 1.83%	32,200 $3.69 Million
Q4 2022 Feb 13, 2023	BUY	$100.86 - $132.13 $2.3 Million - $3.01 Million	22,800 Added 228.0%	32,800 $4.25 Million
Q1 2022 May 16, 2022	BUY	$63.15 - $90.42 $75,780 - $108,504	1,200 Added 13.64%	10,000 $781,000
Q1 2021 May 13, 2021	SELL	$72.25 - $168.95 $5.47 Million - $12.8 Million	-75,700 Reduced 89.59%	8,800 $656,000
Q4 2020 Feb 09, 2021	BUY	$125.56 - $178.74 $10.3 Million - $14.7 Million	82,300 Added 3740.91%	84,500 $2.92 Million
Q3 2020 Nov 05, 2020	BUY	$127.12 - $172.34 $279,664 - $379,148	2,200 New	2,200 $55,000

561

85.5M

3.67M

1.75M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.9B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.